1. Home
  2. JXG vs RANI Comparison

JXG vs RANI Comparison

Compare JXG & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

N/A

Current Price

$10.10

Market Cap

98.9M

Sector

N/A

ML Signal

N/A

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$0.78

Market Cap

106.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JXG
RANI
Founded
N/A
2012
Country
China
United States
Employees
95
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.9M
106.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JXG
RANI
Price
$10.10
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
5.1K
855.1K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.14
EPS
N/A
N/A
Revenue
N/A
$1,633,000.00
Revenue This Year
N/A
$274.77
Revenue Next Year
N/A
$79.44
P/E Ratio
$0.77
N/A
Revenue Growth
N/A
58.85
52 Week Low
$0.23
$0.39
52 Week High
$11.80
$3.87

Technical Indicators

Market Signals
Indicator
JXG
RANI
Relative Strength Index (RSI) 75.18 41.91
Support Level $3.57 $0.71
Resistance Level N/A $1.05
Average True Range (ATR) 0.68 0.05
MACD 0.00 -0.00
Stochastic Oscillator 72.03 28.67

Price Performance

Historical Comparison
JXG
RANI

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: